avatar
Bio Protocol

Following0Followers (X)115.14KPosts94Likes4.57K
avatar

September in the Biosphere 🌐 - Open Science Index: We launched a searchable directory with 6,720 scientific resources. - Launchpad: We added credit-card wallet funding through Privy. - New Bio website: We revamped our website, bringing BIOS, OpenLabs, Buildspace, Launchpad and Biofy together in one place. - PeptAI: Selected for Track 2 of the Adaptyv Bio × Anthropic Protein Design Competition. - NeuroLab Ignition Sale: The sale closed 2.2× oversubscribed, with more than 442K USDC committed by over 650 participants. NDT reward claims for veBIO stakers are now live on https://t.co/Pdf20lmFSy. We also refunded all BioXP spent on the Ignition Sale. Read the full monthly report ↓

avatar

Our Head of BD, Michelangelo (@oxMichelangelo) will be at @ARDD_Meeting in Boston this week until Saturday. If you're building in consumer biotech, rare diseases or longevity and $25–150K could fund your next research step, DM him to meet. We’d also love to chat if you’re an investor with promising projects that are still too early for your fund.

avatar

Congrats to the PeptAI team on being selected for Track 2 of the @adaptyvbio x @AnthropicAI Protein Design Competition! Great to see the team joining researchers from around the world to advance AI-driven protein design and put new designs to the test. Follow @peptai_ to track their progress ↓

avatar

“Science is really the engine of progress for civilization but that engine is kind of stalled a little bit. What we really need is open and permissionless science.” Science should be open to anyone who wants to help move it forward. That’s the idea behind Bio: open research networks where scientists steer AI agents, share evidence others can build on, and work with communities to fund and develop the science they care about.

avatar

The next Ignition Sale is expected to go live on Bio next week! @NootropicsDAO_ is building NeuroLab AI to explore how compounds could affect the brain, from cognition to potential side effects, and help researchers decide what to test in the lab. Use BioXP + USDC to join the sale on @base ↓

avatar

The first reason someone cares about biotech might be their skin, their hair, or the strength they want to keep as they age. @ArtemyShumskiy argues that these desires could help solve longevity biotech’s funding problem. He points to GLP-1s as evidence of the market for outcomes people want and will pay for. The proposal is to make those outcomes the starting point for drug development. Define the improvement in strength, cognition or metabolic health, then work backwards through the biology. That gives researchers a clear goal and investors a clearer picture of demand. This is why we’re looking at consumer biotech as an entry point for Bio Protocol. People can help fund something they want to use and follow what the experiments actually show.

avatar

AI biology is still early enough for its safeguards to be built into the stack. @RANDCorporation maps nine interventions across access to models and data, material screening, detection, attribution and public-health response. No single guardrail can cover a chain running from information to execution. BIOS ( @bioaidevs ) makes the timing concrete. Several stages of computational drug design can already run inside one campaign. Wet-lab proof is the next step. Build the safeguards before the loop closes.

avatar

Congratulations to @adaptyvbio on the $40M. The line worth reading twice is that AI can only move as fast as the experiments behind it. Building throughput on the physical side is slower and less glamorous than model work, and it's what the whole field is actually waiting on. Good to see it funded properly.

avatar

Science pays for the same failure many times over, and nobody involved is doing anything wrong. A lab spends two years on an approach and it doesn't work. That result closes a door, and there are only so many doors, which makes it worth knowing. It goes nowhere. No journal wants it. No grant renewal rewards it. There's a quiet professional cost to saying out loud that two years produced a no. So it stays in the lab, in a drawer, in the memory of a postdoc who has since left for industry. Then another lab has the same idea. It's a good idea, which is why two groups had it. They spend their two years. Same result, same silence. Somewhere a third group is writing the grant application right now. Failure is how the search works. The problem is that each failure gets paid for repeatedly, by people who had no way of knowing it had already been bought. This follows from how research gets funded. The reliable way to be paid is to produce results that look like forward motion, and a no doesn't look like that from the outside. Change who's paying and the pressure changes shape. A group that pooled money to find out whether something works has no stake in the answer being yes. They wanted to know. If it's a no, that's what they bought, and there's nothing to protect by keeping quiet. Most of what follows from that hasn't been built yet. It's a different starting position, and starting positions compound.

avatar

A condition affecting eight thousand people costs about the same to research as one affecting eight million. Same trial design, decade, and regulators. What changes is who you sell the answer to. So for eight thousand people, the answer mostly doesn't get looked for. They aren't a market. They could still be a fund.